JAMA Surg:指南推荐降低风险计划降低外周动脉疾病患者心血管事件的发生

2016-04-09 MedSci MedSci原创

重要性:外周动脉疾病患者(PAD)是心血管事件的高风险因素,但没有研究调查综合风险降低计划对PAD患者长期预后的影响。目标:调查一项针对8个主要指南推荐危险因素管理方法的项目是否可以降低PAD患者心血管事件和肢体事件。设计,设置和参与者:2004年7月1日和2013年3月31日其间,加拿大的研究者使用加拿大,安大略行政数据库中的数据,进行了一项长达7年随访的观察性队列研究。2004年7月至2007

重要性:外周动脉疾病患者(PAD)是心血管事件的高风险因素,但没有研究调查综合风险降低计划对PAD患者长期预后的影响。

目标:调查一项针对8个主要指南推荐危险因素管理方法的项目是否可以降低PAD患者心血管事件和肢体事件。

设计,设置和参与者:2004年7月1日和2013年3月31日其间,加拿大的研究者使用加拿大,安大略行政数据库中的数据,进行了一项长达7年随访的观察性队列研究。2004年7月至2007年4月期间,在安大略一个三级血管中心招募有症状的PAD患者纳入系统评价血管风险计划(SAVR),并且应用倾向性评分方法,按照1:2,在安大略其他三级血管中心选取PAD患者作为对照组。应用Cox比例风险回归分析比较预后。计划主要由血管外科医生,家庭医生及PAD患者参与,包括抗血小板、他汀类药物应用、血管紧张素转换酶抑制剂应用,控制血压,调节血脂,控制糖尿病血糖,戒烟及BMI指数达标。

主要预后和措施:主要终点是死亡、急性心肌梗死或缺血性卒中的复合危险率。次要终点包括下肢截肢率,旁路手术和有无支架的外周血管成形术。

结果:倾向得分匹配研究后共791例纳入研究;SAVR组(n = 290)的平均年龄(SD)是67.9(10.4)岁,对照组(N = 501)的平均年龄(SD)为68.2(11.2)岁。随访期间,SAVR组的主要预后显著低于对照组(aHR ,0.63;95% CI,0.52-0.77)。SAVR组患者大截肢(aHR、0.47;95 % CI,0.29-0.77)、小截肢(aHR、0.26;95% CI,0.13-0.54),旁路手术(aHR、0.47;95% CI,0.30-0.73)或住院因心脏衰竭(aHR 0.73;95% CI,0.53-1.00)的可能性较低。SAVR组患者有无支架的外周血管成形术较高(aHR、2.97;95% CI,2.15-4.10)。

结论与相关性:针对PAD患者的指南推荐降低风险计划与长期的心血管事件和肢体事件发生减少相关。这一发现强调需要精心设计前瞻性的研究,建立相应的降低PAD患者发病率,死亡率及医疗保健费用的计划。

原文出处:

Hussain MA, Al-Omran M, et al. Efficacy of a Guideline-Recommended Risk-Reduction Program to Improve Cardiovascular and Limb Outcomes in Patients With Peripheral Arterial Disease. JAMA Surg. 2016 Apr 6.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643405, encodeId=76b41643405a2, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jun 22 20:51:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798956, encodeId=edcc1e98956ae, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 22 19:51:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78121, encodeId=1fe4e812145, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78122, encodeId=8569e8122a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593265, encodeId=256315932653c, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 11 05:51:00 CST 2016, time=2016-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643405, encodeId=76b41643405a2, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jun 22 20:51:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798956, encodeId=edcc1e98956ae, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 22 19:51:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78121, encodeId=1fe4e812145, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78122, encodeId=8569e8122a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593265, encodeId=256315932653c, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 11 05:51:00 CST 2016, time=2016-04-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643405, encodeId=76b41643405a2, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jun 22 20:51:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798956, encodeId=edcc1e98956ae, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 22 19:51:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78121, encodeId=1fe4e812145, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78122, encodeId=8569e8122a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593265, encodeId=256315932653c, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 11 05:51:00 CST 2016, time=2016-04-11, status=1, ipAttribution=)]
    2016-04-14 李继凯

    文章不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1643405, encodeId=76b41643405a2, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jun 22 20:51:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798956, encodeId=edcc1e98956ae, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 22 19:51:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78121, encodeId=1fe4e812145, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78122, encodeId=8569e8122a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593265, encodeId=256315932653c, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 11 05:51:00 CST 2016, time=2016-04-11, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1643405, encodeId=76b41643405a2, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Wed Jun 22 20:51:00 CST 2016, time=2016-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798956, encodeId=edcc1e98956ae, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jan 22 19:51:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78121, encodeId=1fe4e812145, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78122, encodeId=8569e8122a2, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:32:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593265, encodeId=256315932653c, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Mon Apr 11 05:51:00 CST 2016, time=2016-04-11, status=1, ipAttribution=)]

相关资讯

美国外周动脉疾病(PAD)血管内介入治疗共识声明

2014年5月28日,美国心血管造影和介入学会(SCAI)发布了最新的外周动脉疾病血管内介入治疗共识声明。根据共识,几乎所有的主-髂动脉外周动脉疾病(PAD)都可以采用血管内介入治疗,没有证据显示某一种支架优于其他类型的支架。对于TASC分级为A、B、C级的主-髂动脉PAD,血管内介入治疗优于内膜切除术,证据表明前者在降低患者死亡率方面更具优势(动脉内膜切除术住院死亡率2.7%)。共识声明主要作者

Nat Biotechnol:新技术助推血管再造

近日,一项发表在国际杂志Nature Biotechnology上的研究论文中,来自印第安纳大学医学院的科学家开发了一种新型技术可以启动机体产生血管组织,为开发治疗因截肢及个体失明而引发的相关疾病的新型疗法带来了帮助。 文章中,研究者人员表示,这种新型技术为开发治疗外周动脉疾病的新型疗法提供了一定思路,外周动脉疾病因血流不畅引发的腿部疼痛疾病,其会引发皮肤坏疽,严重情况下需要对患者进行截肢

Int J Cardiol:外周动脉疾病和房颤是卒中、心衰及心血管死亡的独立危险因素

背景:外周动脉疾病(PAD)和心房颤动(AF)存在许多共同并发病,并且导致相同的心血管(CV)预后。只有少数的研究评估PAD,AF,及对CV预后的影响的相关性。方法:研究者选取来自台湾国家健康保险研究数据库的597164名成年人进行一项队列研究,以评估PAD是否是房颤的独立危险因素,房颤是否是PAD的独立危险因素。研究者确定PAD和房颤是否增加卒中的发生,心脏衰竭住院及心血管死亡。结果:存在PAD

BMJ:血压增高是外周动脉疾病的危险因素

近期Emdin CA等人对420万名成年人进行了一项队列研究,探究血压与外周动脉疾病的关系,以及外周动脉疾病与其他类型血管疾病的风险间联系。研究者根据英国1990-2013年电子医疗记录里检索相关信息,纳入研究对象年龄在30-90岁,共计4 222 459名,并且有≥1年的血压监测管理记录。研究者以第一次诊断新发病外周动脉疾病的时间,以及第一次诊断其他不同类型血管疾病时间作为研究终点或观察指标。研

JAMA:地中海饮食与外周动脉疾病的较低风险有关

据1月22/29日发表在《美国医学会杂志》JAMA上的一则研究披露,在西班牙开展的一项多中心研究发现,一种辅以特级初榨橄榄油或坚果的地中海饮食与外周动脉疾病的较低风险有关。 根据文章 的背景资料,地中海饮食可降低心脏病发作及中风的风险,还可降低外周动脉疾病(PAD)的风险,但这种假说还从来没有经过随机性试验的检测。 西班牙潘普洛纳市纳瓦拉大学的Miguel Ruiz-Canela, Ph.D.

Heart:预防外周动脉疾病 选阿托伐他汀还是辛伐他汀?

多国学者探讨了大剂量和常规剂量的他汀类药物治疗是否可减少外周动脉疾病(PAD)的发生率,以及大剂量他汀治疗对合并PAD患者的心血管疾病(CVD)转归的影响。结果显示,与常规剂量辛伐他汀相比,大剂量阿托伐他汀显著减少PAD的发生率。基线时有PAD病史的患者将来发生冠脉事件的风险较高,而大剂量阿托伐他汀治疗可减少这一风险。相关论文1月16日在线发表于《心脏》(Heart)杂志。 研究者们纳入